Markets:

Overview

News

Currencies

International

Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

13.29 -0.32 (-2.35%)

Streaming Delayed Price Updated: 12:48 PM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

April 04, 2023

From Silence Therapeutics plc

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

March 29, 2023

On Wednesday, 81 companies hit new 52-week lows.

Via Benzinga

Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

March 29, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study ↗

September 29, 2022

Via Benzinga

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

March 28, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Buyback siRNA Complement Assets

March 28, 2023

From Silence Therapeutics plc

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 15, 2023

Via Benzinga

Earnings Scheduled For March 15, 2023 ↗

March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

Via Benzinga

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

March 15, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

March 02, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

February 08, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

February 06, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

January 12, 2023

From Silence Therapeutics

Via Business Wire

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Silence Therapeutics

Via Business Wire

Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗

November 25, 2022

Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.

Via Benzinga

Silence Therapeutics Reports Third Quarter 2022 Results

November 10, 2022

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at Jefferies London Healthcare Conference

November 09, 2022

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

November 05, 2022

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

September 29, 2022

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

September 27, 2022

From Silence Therapeutics plc

Via Business Wire

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗

September 08, 2022

Via Benzinga

Silence Therapeutics Gets FDA Fast Track Status For Blood Cancer Candidate ↗

September 08, 2022

Silence Therapeutics (NASDAQ: SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera...

Via Benzinga

Silence Therapeutics to Participate in September Investment Conferences

September 08, 2022

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

September 08, 2022

From Silence Therapeutics plc

Via Business Wire

Workday, Electronic Arts, Ulta Beauty And Some Other Big Stocks Moving Higher On Friday ↗

August 26, 2022

Micro Focus International plc (NYSE: MFGP) shares jumped 95.4% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

Silence Therapeutics Announces Pricing of Underwritten Offering

August 11, 2022

From Silence Therapeutics plc

Via Business Wire

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗

August 19, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Via Benzinga

Silence Therapeutics to Present at Jefferies Healthcare Conference

June 02, 2022

From Silence Therapeutics plc

Via Business Wire

Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

August 18, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.

Via Benzinga

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗

June 23, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.